Zanzalintinib
4 abstracts
Abstract
STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma.Org: Winship Cancer Institute, Emory University, Atlanta, GA, USA, The Institute of Cancer Research/The Royal Marsden Hospital, Fondazione IRCCS Istituto Nazionale Tumori and University of Milan, Cliniques Universitaires Saint-Luc,
Abstract
Zanzalintinib (XL092) plus nivolumab in non-clear cell renal cell carcinoma: The randomized phase 3 STELLAR-304 study.Org: Barts Health NHS Trust Saint Bartholomew’s Hospital,
Abstract
Biomarker analysis of zanzalintinib in clear cell renal cell carcinoma from STELLAR-001.Org: APHP Hôpital Européen Georges Pompidou and Université Paris Cité, Charles University and Thomayer University Hospital, Institut de Cancérologie Gustave Roussy,
Abstract
STELLAR-303: A randomized phase 3 study of zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated metastatic colorectal cancer.Org: Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC,